Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xbrane Biopharma AB

http://xbrane.com/

Latest From Xbrane Biopharma AB

Xbrane Refiles Ranibizumab With US FDA

Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.

Biosimilars United States

Stada, Biogen Bring Greater Ranibizumab Competition To EU And UK

April brings news of further biosimilar competition to Lucentis in major European markets.

Biosimilars Launches

Xbrane Eyes Positive Cash Flow In 2024 – But Out-Licensing Oncology Key

Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.

Biosimilars Sales & Earnings

Stada And Xbrane Receive MHRA Nod For Ranibizumab

Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.

Approvals Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Primm Pharma Srl
UsernamePublicRestriction

Register